Johnson & Johnson (NYSE:JNJ) Shares Acquired by Intact Investment Management Inc.

Intact Investment Management Inc. increased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.2% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 87,289 shares of the company's stock after purchasing an additional 2,700 shares during the quarter. Intact Investment Management Inc.'s holdings in Johnson & Johnson were worth $14,476,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Burt Wealth Advisors increased its holdings in shares of Johnson & Johnson by 3.1% in the 1st quarter. Burt Wealth Advisors now owns 12,778 shares of the company's stock worth $2,119,000 after purchasing an additional 381 shares in the last quarter. Center For Asset Management LLC purchased a new position in shares of Johnson & Johnson in the first quarter valued at about $205,000. Bernardo Wealth Planning LLC lifted its position in shares of Johnson & Johnson by 2.4% in the first quarter. Bernardo Wealth Planning LLC now owns 6,493 shares of the company's stock valued at $1,077,000 after acquiring an additional 155 shares in the last quarter. Canton Hathaway LLC increased its holdings in shares of Johnson & Johnson by 22.9% in the first quarter. Canton Hathaway LLC now owns 7,075 shares of the company's stock worth $1,173,000 after purchasing an additional 1,318 shares during the last quarter. Finally, Register Financial Advisors LLC increased its holdings in shares of Johnson & Johnson by 1.2% in the first quarter. Register Financial Advisors LLC now owns 15,388 shares of the company's stock worth $2,552,000 after purchasing an additional 186 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Up 1.0%

Shares of JNJ stock traded up $1.54 during trading on Monday, hitting $151.33. 7,269,653 shares of the stock traded hands, compared to its average volume of 7,990,923. The firm has a market capitalization of $364.11 billion, a P/E ratio of 16.83, a price-to-earnings-growth ratio of 2.27 and a beta of 0.42. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The firm's fifty day moving average price is $154.07 and its 200-day moving average price is $153.68.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. As a group, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.44%. The ex-dividend date was Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is 57.84%.

Analyst Ratings Changes

Several equities research analysts have weighed in on JNJ shares. Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Morgan Stanley lifted their price target on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 16th. Raymond James Financial dropped their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Finally, Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Eleven analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.